Skip to main content
Autolus Therapeutics plc logo

Autolus Therapeutics plc — Investor Relations & Filings

Ticker · AUTL ISIN · US05280R1005 LEI · 549300C0KZP8EYROLL02 US Manufacturing
Open in API
Filings indexed 298 across all filing types
Latest filing 2026-06-09 Report Publication Anno…
Country GB United Kingdom
Listing US AUTL

About Autolus Therapeutics plc

https://www.autolus.com/

Autolus Therapeutics plc is a commercial-stage biopharmaceutical company developing next-generation, programmed T cell therapies for cancer and autoimmune diseases. The company specializes in Chimeric Antigen Receptor (CAR) T-cell technology, which reprograms a patient's own T cells to recognize and eliminate disease cells. Its lead therapy, obecabtagene autoleucel (obe-cel), is approved for the treatment of adult relapsed/refractory B-cell Acute Lymphoblastic Leukemia (ALL). Autolus leverages its advanced cell programming capabilities and proprietary manufacturing processes to develop a pipeline of precise and controlled autologous therapies targeting hematological malignancies, solid tumors, and autoimmune conditions.

Recent filings

Filing Released Lang Actions
8-K
Report Publication Announcement Classification · 82% confidence The document is an SEC Form 8-K “Current Report” under Item 8.01 “Other Events” that notifies investors that the company has published its UK Annual Report and Accounts and distributed proxy materials for the upcoming AGM. It does not contain the actual annual report financial statements or substantive financial data itself but merely announces the availability of those documents (Exhibits 99.1–99.3) and where they can be accessed. This matches the definition of a Report Publication Announcement (RPA): an announcement regarding the release/publication of company reports. Therefore, the correct classification is RPA.
2026-06-09 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-14 English
8-K
Report Publication Announcement Classification · 84% confidence The document is a U.S. SEC Form 8-K “Current Report” that does not itself contain the full financial results or presentation but instead “furnishes” a press release (Exhibit 99.1) announcing quarter-end results and a corporate presentation (Exhibit 99.2). It is not the substantive earnings release or presentation itself, nor is it a management discussion or interim report with full financial statements. Rather, it simply announces the publication and attaches those exhibits. This matches our definition of a Report Publication Announcement (RPA).
2026-05-14 English
8-K - Autolus Therapeutics plc (0001730463) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The content describes a workforce reduction plan approved by the Board of Directors, including severance costs and operational efficiency measures. It also references a press release and financial guidance update. There are no detailed financial statements or comprehensive financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). The document is not a transcript, proxy, or governance report. It is a regulatory filing reporting a significant corporate event (workforce reduction and cost restructuring). Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2026-04-29 English
8-K - Autolus Therapeutics plc (0001730463) (Filer)
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions Item 7.01 Regulation FD Disclosure about a virtual investor event and presentation materials posted on the company's website. The presentation is attached as Exhibit 99.1. The document explicitly states that the information is "furnished" and not "filed" for certain regulatory purposes, indicating it is an announcement rather than a full report. The content is a disclosure of an investor presentation event and the availability of presentation materials, not the presentation itself or a detailed financial report. Therefore, the document fits best into the category of Investor Presentation (IP) as it relates to a detailed presentation for investors focusing on financials, strategy, and market position, which is being disclosed via this Form 8-K filing.
2026-04-08 English
10-K - Autolus Therapeutics plc (0001730463) (Filer)
Annual Report FY 2025
2026-03-27 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.